Corrigendum to 'Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine in front-line metastatic pancreatic cancer (CARRIE)': Annals of Oncology, Volume 31, Issue 1, 2020, Pages 79-87

Affiliations

• ¹ Medical Oncology, Banner MD Anderson Cancer Center, Gilbert, USA.
• ² Medical Oncology, Centro Integral Oncologico Clara Campal, Universidad CEU San Pablo, Madrid, Spain; Departamento de Ciencias Médicas Clínicas, Universidad CEU San Pablo, Madrid, Spain.
• ³ Hematology and Oncology, Florida Cancer Specialists, Fort Myers, USA.
• ⁴ Medical Oncology, Comprehensive Care and Research Center, Atlanta, USA.
• ⁵ GI Oncology, Sarah Cannon Research Institute/Tennessee Oncology, Nashville, USA.
• ⁶ TUM School of Medicine, Klinikum rechts der Isar, Medizinische Klinik II, Technical University of Munich, Munich, Germany.
• ⁷ Medical Oncology, Hospital Universitario Marques de Valdecilla, Santander, Spain.
• ⁸ Medical Oncology, Cancer Treatment Centers of America Chicago, Zion, USA.
• ⁹ Department of Medicine, Royal Marsden Hospital, Sutton, UK.
• ¹⁰ Charité - Universitätsmedizin, Berlin, Germany.
• ¹¹ Hematology/Oncology, Pacific Cancer Medical Center, Anaheim, USA.
• ¹² Clinical Development, Merrimack Pharmaceuticals, Inc., Cambridge, USA.
• ¹³ Hematology/Oncology, University of California San Francisco Cancer Center, San Francisco, USA. Electronic address: andrew.ko@ucsf.edu.